On September 1, 2020 BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), along with its specialty oncology division, GenPath, reported the launch of OnkoSight AdvancedTM, a next-generation sequencing (NGS) assay that enables revolutionary deoxyribonucleic acid (DNA) mutational profiling of tumor samples (Press release, Opko Health, SEP 1, 2020, View Source [SID1234564262]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

OnkoSight Advanced NGS testing provides targeted gene content that is aligned with the latest National Comprehensive Cancer Network (NCCN) and World Health Organization (WHO) guideline recommendations, to provide critical insights into many of the most common cancer types. Additionally, OnkoSight Advanced panels each include key biomarkers: Tumor Mutation Burden (TMB) and Tumor-Only Microsatellite (MSI), which are critical when profiling advanced stage tumor malignancies to guide potential immunotherapy.

"OnkoSight Advanced NGS panels are tumor-type specific and optimized to exclude extraneous gene content, significantly improving clinical actionability and relevance of the data to effectively guide real-world oncology patient management," said Bevan Tandon, M.D., Hematopathologist and Molecular Pathologist, Director of Cancer Genomics at BioReference Laboratories. "Coupled with BioReference and GenPath’s comprehensive oncology test menu, OnkoSight Advanced empowers physicians to make informed decisions effectively and efficiently."

"A cancer diagnosis and treatment path are difficult to address with patients and their families, which drives the importance of understanding a patient’s risk group and accurately diagnosing the type of cancer, to result in a targeted treatment strategy and prognosis assessment," said Jon R. Cohen, M.D., Executive Chairman of BioReference Laboratories. "The latest advancement from BioReference’s oncology division underscores the commitment to patient-centric care through our industry-leading result turnaround time with enhanced accuracy."

On September 1, 2020 The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) reported plans to develop a program to scientifically evaluate and facilitate clinical trials on the efficacy of decitabine and cedazuridine (Press release, NCCN, SEP 1, 2020, View Source [SID1234564261]). This novel, fixed dose combination of the hypomethylating agent decitabine, combined with the cytidine deaminase inhibitor cedazuridine permits effective oral administration of decitabine by preventing degradation in the gut and liver. Studies will investigate decitabine and cedazuridine in hematologic malignancies. Research funding will be provided by a $2 million grant from Taiho Oncology.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Patients and advocates frequently express preference for oral medications over intravenous infusions," said Wui-Jin Koh, MD, Chief Medical Officer, NCCN. "By learning more about how patients with various cancer types respond to this kind of treatment when it’s delivered in an oral dosage form, we have the potential to make great strides in improving comfort, convenience, treatment adherence, and hopefully cure rates."

"The National Comprehensive Cancer Network’s research on decitabine and cedazuridine tablets can provide important insights regarding oral treatment options for patients with hematologic malignancies that can be taken from their home," said Martin J. Birkhofer, MD, Senior Vice President and Chief Medical Officer, Taiho Oncology, Inc. "We thank NCCN for expanding the generation of clinical data for decitabine and cedazuridine in patients with hematologic malignancies. This research is significant as both patients and healthcare providers look to reduce the number of in-office visits required for intravenous administration of their treatment during the current global pandemic."

The specific tumor types to be targeted for study will be determined by a group of cancer research specialists from NCCN Member Institutions who form the Request for Proposals (RFP) Development Team. The RFP will be shared in the coming months, with an announcement of selected projects to follow.

The NCCN ORP fosters innovation and knowledge discovery that improves the lives of people with cancer and supports preclinical, translational, clinical research and quality improvement projects in oncology at NCCN Member Institutions. In an effort to improve collaboration in cancer research, the NCCN ORP also maintains a shared resources website and an informed consent database. For more information, visit NCCN.org/orp.

On September 1, 2020 Benitec Biopharma, Inc. (NASDAQ: BNTC), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ("ddRNAi") platform, reported that Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec Biopharma will present at the H.C. Wainwright 22nd Annual Global Investment Conference (Press release, Benitec Biopharma, SEP 1, 2020, https://www.prnewswire.com/news-releases/benitec-biopharma-to-present-at-hc-wainwrights-22nd-annual-global-investment-conference-301121597.html [SID1234564260]). The relevant details are outlined below:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Wednesday, September 16, 2020
Event: H.C. Wainwright 22nd Annual Global Investment Conference
Time: 11:30 A.M. EDT
Webcast Link: View Source

Please visit the link above to register for the presentation which will be presented via webcast during the virtual conference. The presentation will also be streamed on the Investor Relations section of the Company’s website, View Source, and a copy of the presentation will be released to Nasdaq and posted on the Company’s website at the above URL prior to the event.

If you would like to arrange a virtual 1×1 meeting with Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec after the presentation, please contact the Benitec IR Team using the details below.

On September 1, 2020 Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, reported that management will participate in four investor conferences in September (Press release, Eiger Biopharmaceuticals, SEP 1, 2020, View Source [SID1234564259]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi’s 15th Annual BioPharma Conference. Eiger will participate in two panels:
"COVID-19 Therapeutics" on Wednesday, September 9, 9:50-10:20 AM ET
"Challenges and Opportunities in Rare Disease Drug Development" on Wednesday, September 9, 4:15-4:45 PM ET

Baird Global Healthcare Conference 2020. Eiger will present a corporate update on Wednesday, September 9, 12:50-1:20 PM ET.

H.C. Wainwright 22nd Annual Global Investment Conference from September 14- September 16.

Cantor Global Virtual Healthcare Conference 2020. Eiger will present a corporate update on Thursday, September 17, 2:00-2:30 PM ET.
Eiger will host one-on-one meetings at all conferences. Live webcasts of the Citi panels and Baird and Cantor presentations will be available on the Eiger BioPharmaceuticals website at www.eigerbio.com under the "Investors" tab. A replay of the webcast will be available approximately one hour following the live event.

On September 1, 2020 Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, reported that D. Keith Grossman, Nevro’s Chairman, CEO and President, will present at the following conferences (Press release, Nevro, SEP 1, 2020, View Source [SID1234564258]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Wells Fargo 2020 Virtual Healthcare Conference
Wednesday, Sept. 9, 2020 at 4:00 pm ET

Morgan Stanley 18th Annual Global Healthcare Conference
Monday, Sept. 14, 2020 at 3:00 pm ET

A live webcast of these events will be available on the Investors section of Nevro’s website at www.nevro.com. A webcast replay will be available approximately one hour after each live webcast ends and will be accessible for approximately 14 days.